Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nuke, I can call my part d ins, cvs and ask. I'll let you know.
dar53, I believe it is Medicare who determines pricing and or tier. I love that CVS doesn't offer GV at all! They have a new female CEO who happens to be very smart. The PBM's have a hold on what's covered or not too. They should outlaw them. Mark Cuban started his own online drug offerings for generics. Keep an eye on his venture very interesting. Its name is Cost Plus Drug Co.
dar53, if you check with humana's pbm and request a 100 day supply you will get an additional 10 day supply for the same amount of $. CVS caremark has V as a tier 3. saves me a ton of money annually.
Do patients benefit from omega-3 fatty acids? https://t.co/mhWAyMnPMC #cardiology #cardiotwitter #prevention @gabrielsteg
— Dr. Deepak L. Bhatt (@DLBHATTMD) February 18, 2024
Capt found this release on X not sure if it's been posted here. "It's the EPA stupid" as you would say.....
https://academic.oup.com/cardiovascres/article/119/18/2884/7585216?login=false
Golf stud. I agree. Usually they send emails with information re call in number etc
Denisk, I guess we'll know more tomorrow morning. If so it's very unprofessional to keep everyone in the dark.
I found on bing March 6, 2024 will be YE report. So confusing with everything re Amarin! Their proxy was filed recently with a date in April for a vote. Hopefully, they'll get that out of the way so they can start buying the stock in open mkt. It's financial engineering but at this juncture, I don't give a rats a--s as long the price goes up.
I googled the question and 3/4/24 showed up for a conf call but Fidelity has it listed for tomorrow as does the Yahoo article from a couple of wks ago. Weird.
Does anyone have the the call in number and code for the conference call? Has anyone tried to navigate their website? It's useless. They usually have a link to the call info. Actually, I complained about the sh--y website but of course no response.
Kiwi: Problem is cost. Bloomberg is very expensive usually people in Wall St have access to Bloomberg thru their company. Maybe full time traders or hedgies too.
fyi:
HLS news
News Release Issued: Feb 6, 2024 (6:30am EST)
To view this release online and get more information about HLS Therapeutics Inc. visit: https://hlstherapeutics.investorroom.com/2024-02-06-HLS-Announces-that-Vascepa-R-is-now-reimbursed-by-British-Columbias-Provincial-Drug-Plan
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
• Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, Veterans Affairs and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples.
• Approximately 14% of all Canadians live in British Columbia1.
• Pacific Blue Cross, British Columbia's largest private health plan, also expected to reimburse Vascepa starting in February.
TORONTO, Feb. 6, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of British Columbia ("BC"), for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with BC PharmaCare is effective February 6, 2024.
Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by BC PharmaCare for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.
The PLA with BC PharmaCare also paves the way for Vascepa to be reimbursed by Pacific Blue Cross, which provides healthcare benefits for approximately 40%2 of the privately insured lives in BC. The Pacific Blue Cross reimbursement process for Vascepa is near completion and is also expected to take effect this month.
"The Product Listing Agreement with BC PharmaCare, and the subsequent listing by Pacific Blue Cross, will significantly improve access and reimbursement throughout Canada's third largest province," said Craig Millian, CEO of HLS. "Cardiovascular disease remains one of the leading killers worldwide, so we are very pleased that Vascepa will now be more accessible to a greater number of BC residents who are eligible for treatment."
Approximately 14% of all Canadians live in BC1. As disclosed previously, HLS has achieved public reimbursement for Ontario, Quebec, Saskatchewan, New Brunswick, Northwest Territories, Veterans Affairs and the NIHB program for First Nations and Inuit peoples.
ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES
Vascepa capsules are the first-and-only prescription treatment comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. Vascepa was approved by Health Canada and added to Health Canada's Register of Innovative Drugs and benefits from data protection for a term of eight years, as well as being the subject of multiple issued and pending patents based on its unique clinical profile. HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corporation (NASDAQ:AMRN).
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases, the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to the composition of HLS's board of directors. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 15, 2023, and Management's Discussion and Analysis dated November 8, 2023, both of which have been filed on SEDAR+ and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly
ziploc, assuming the method of delivery is oral why wouldn't the current V formula hit the lymphatic system as well? Maybe once a day dose taken at bedtime? Just guessing I Know Nothing!
Capt. wouldn't it be nice if the Teva drop out of mkt be a sign of others to drop out as well.... excluding Hikma and DRL.
👍👍👍👍👍👍
Hey, LBL why do you think this will be the norm with GV companies? Is it not worth their effort due to low margins and availability? Maybe the Healthnet settlement had something to do with the GV companies backing off? When CVS Caremark stopped selling GV it was the beginning of the end. Stock trades like a schizophrenic bipolar piece of shit. Maybe the earnings call on 2/14 management will provide future positive direction and the dopey analyst will turn bullish? Ha.
I wonder if TEVA dropping out of the API business includes GV? Does anyone have additional input?
https://endpts.com/teva-plans-sale-of-api-unit-amid-pivot-to-growth/
yeah wonder what that was all about??? Over 1,500,000 mill shs. A late print from a seller prolly HF can't confirm whether it was a sale or not. Recently I've noticed that trades in the middle of the spread appear to be sales but are buys.
Meow, after I read the post about scamming the ihub posters it piqued my interest as i didn't realize how devious he is to write something that would piss off many then he captures the ST board and spews his BS.
Boom, they took out the $1.30 offerings in a heartbeat. There were about 55,000 shs offered now they're gone!
meowza, the nut job is currently posting every day on ST. He needs to start new meds what a waste of human flesh.
Orbapu, thanks for the technical analysis. I think the last sentence is in question cause of the recent events the stock feels like it will continue higher once it moves to a level where accumulation continues with plenty of news in the pipeline sometimes the technicals have to be considered along with positive company announcements and the $50mill buyback in the second half of '24 we should be in a good place. As the old saying goes....😂 Baby needs new shoes!
ramfan, backstroking on the Riviera with a pina colada
meowza, seriously? pdude is a pompous a--hole since I placed him on ignore I guess I've missed the fun!🤣
ramfan, there's been several block trades that happened in the past hour or so which cleaned up a bunch of loose mid-day sellers. We may have finally seen the bottom. I'm sure Holt's legal team is writing the letter to FINRA to inform them of the company's compliance with $1.00 minimum share price.
CBB, Trying to figure out how to price V if it's sold to BP is a guessing game. Too many unknown factors. Future events will play a big role in the equation. I think Morgan Stanley will be the go to broker for M&A. Based on most Wall st gurus this year will be the year for long overdue M&A activity in the biotech space.🤞
Since I've been involved in this stock I don't recall any upper management buying stock in the open mkt except for Ketchum a few yrs ago. Maybe LBL is guiding us correctly into the bull camp for 2024?
Anyone notice the vol before the opening? Nice start.
Jasbg, almost all HF have a similar setup. For a few reasons. Mainly taxes. It's not illegal.
Kiwi, so truth be told you are clueless. Why start fud? There's enough of that BS here without your assumptions.
kiwi, I still don't understand. Did Kaiser stop selling branded V altogether? Did your doc indicate DAW. Then the druggist gave you GV?
kiwi, I don't understand your reply. V still is being sold as V not a generic. Has Kaiser stopped selling branded V?
Re your statement about expire my recent refill expiration date is good for over a yr.
Jasbg, the only way anyone would know about the function of any HF is to read their charter. You ASSUME too much about the operation of Sarissa. I doubt that AD would short a stock in his portfolio, he may hedge his positions using derivatives and keep in mind as LBL mentioned GS being pissed and are living up to their reputation as being total A--holes. Also have a sell rating on AMRN.
DAR/JRoon. Yup the filing of the proxy will prolly be in April then a 30 day vote period. The annual meeting announcing results and filing final proxy will bring us into early Q3. Everything takes time. Plus I believe certain rules exist while executing the buyback e g quiet periods and vwaps. So the answer to the question about blowing the wad at once ain't going to happen.
OK, LBL aka "Little Birdie", I'll give you the China call. They're in a death spiral Pres XI Jinping is kissing ass, after '24 we'll be in a better bargaining position. Given Denner's reputation for getting things done I've always believed his connections would pull us through to a positive place. Especially after the conversation I had with the proxy solicitor last yr.
Jasbg, the company can't start the buyback till shareholder approval which won't be till they get the results of the proxy vote. they estimate will be sometime in spring I'm hoping early spring rather than waiting till June.
Hey, LBL, with China's economy in the crapper why do you think they will be in the equation for growth? However, my instincts have been telling me there's something brewing. Branded generic in the USA will be the first dramatic move. Margins will be lower but they'll make it up in volume. The DEF14 can't come soon enough for the buyback. Normally, I despise buybacks it's just financial rigging to meet street EPS but in the case of Amarin it's significant and tells a deeper behind the scenes story. Please continue to keep us in the loop.
LBL, Holt may be conservation re the Germany approval since the prior management prolly f--kd up too many events leading to the disappointing denial of approval. Not to mention all the millions wasted with the assumption leading up to the termination of approval.
Your post is encouraging since it's in line with my belief the rollout in the EU was akin to a startup. Fortunately, we have no debt. Re the antitrust Reddys, it's BS. Thanks for the positive uptick on the China front. I'd given up on the Pacific rim with all the political turmoil.
Second half of 2024 will be fun to experience after so many years of disappointment.
I believe the company will fast track the annual meeting so they can start the buyback. ASAP.
Pls stay in touch!
seve, last I inquired at Fidelity they said they will not permit an acct to short this stock unless the account has a minimum of $2.50 in cash for each share shorted. Who in their right mind would short AMRN with that type of requirement? Fidelity considers it to risky given the past trading history of AMRN. Maybe requirements are different at the brokerage firm you use? You should ask them....